Pfizer (NSEI:PFIZER) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

PFIZER Overzicht aandelen

Pfizer Limited houdt zich bezig met de productie, marketing, handel en export van farmaceutische producten in India en internationaal.

Over het bedrijf

PFIZER fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	2/6
Financiële gezondheid	5/6
Dividenden	3/6

Beloningen

De winst zal naar verwachting met 13.41% per jaar groeien

Risicoanalyse

Onstabiel dividend track record

Pfizer Limited Concurrenten

Emcure Pharmaceuticals

NSEI:EMCURE

₹269.8b

Suven Pharmaceuticals

NSEI:SUVENPHAR

₹305.4b

Laurus Labs

NSEI:LAURUSLABS

₹240.0b

Concord Biotech

NSEI:CONCORDBIO

₹201.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Pfizer
Historische aandelenkoersen
Huidige aandelenkoers	₹5,616.40
52 Week Hoogtepunt	₹6,451.15
52 Week Laag	₹3,838.00
Bèta	0.25
11 maand verandering	-8.81%
3 maanden verandering	21.40%
1 Jaar Verandering	40.79%
33 jaar verandering	1.19%
5 jaar verandering	79.33%
Verandering sinds IPO	298.75%

Recent nieuws en updates

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Aug 31

Recent updates

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Aug 31

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Aug 07

This Is The Reason Why We Think Pfizer Limited's (NSE:PFIZER) CEO Deserves A Bump Up To Their Compensation

Aug 12

Are Institutions Heavily Invested In Pfizer Limited's (NSE:PFIZER) Shares?

Mar 10

Why Dividend Hunters Love Pfizer Limited (NSE:PFIZER)

Feb 17

Are Pfizer's (NSE:PFIZER) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 02

Rendement voor aandeelhouders

	PFIZER	IN Pharmaceuticals	IN Markt
7D	-3.7%	-0.4%	-2.6%
1Y	40.8%	60.6%	42.2%

Rendement versus industrie: PFIZER presteerde slechter dan de Indian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 59.4 % opleverde.

Rendement versus markt: PFIZER presteerde slechter dan Indian Market, dat het afgelopen jaar een rendement van 44.6 % opleverde.

Prijsvolatiliteit

Is PFIZER's price volatile compared to industry and market?
PFIZER volatility
PFIZER Average Weekly Movement	4.7%
Pharmaceuticals Industry Average Movement	6.1%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.3%
10% least volatile stocks in IN Market	3.9%

Stabiele aandelenkoers: PFIZER heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van PFIZER is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1950	1,721	Meenakshi Nevatia	www.pfizerltd.co.in

Pfizer Limited houdt zich bezig met de productie, marketing, handel en export van farmaceutische producten in India en internationaal. Het biedt zijn producten aan in verschillende therapeutische gebieden, waaronder neuro/CNS, hormonen, cardiovasculair, hemofilie, anti-infectiva, gynaecologie, pijn/analgetica, orthopedie, oncologie, urologie, anti-parasitaire, gastro-intestinale, vaccins en ademhalingsziekten, evenals vitaminen, mineralen en voedingsstoffen. Het bedrijf biedt ook diensten op het gebied van interne geneeskunde en anti-infectiva aan ziekenhuizen en verpleeghuizen.

Pfizer Limited Samenvatting

Hoe verhouden de winst en inkomsten van Pfizer zich tot de beurswaarde?
PFIZER fundamentele statistieken
Marktkapitalisatie	₹256.94b
Inkomsten(TTM)	₹6.09b
Inkomsten(TTM)	₹22.25b

42.2x

Koers/Winstverhouding

11.5x

P/S-verhouding

Is PFIZER overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PFIZER resultatenrekening (TTM)
Inkomsten	₹22.25b
Kosten van inkomsten	₹7.77b
Brutowinst	₹14.47b
Overige uitgaven	₹8.39b
Inkomsten	₹6.09b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 14, 2024

Winst per aandeel (EPS)	133.01
Brutomarge	65.06%
Nettowinstmarge	27.35%
Schuld/Eigen Vermogen Verhouding	2.6%

Hoe presteerde PFIZER op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.6%

Huidig dividendrendement

29%

Uitbetalingsratio

PFIZER Overzicht aandelen

Beloningen

Risicoanalyse

Pfizer Limited Concurrenten

NSEI:EMCURE

₹269.8b

NSEI:SUVENPHAR

₹305.4b

NSEI:LAURUSLABS

₹240.0b

NSEI:CONCORDBIO

₹201.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

High number of new directors

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Pfizer Limited Approves to Declare A Dividend for the Financial Year Ended March 31, 2024

Dividend of ₹35.00 announced

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Recent updates

High number of new directors

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Pfizer Limited Approves to Declare A Dividend for the Financial Year Ended March 31, 2024

Dividend of ₹35.00 announced

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Price target increased by 11% to ₹5,477

First quarter 2025 earnings released: EPS: ₹32.94 (vs ₹20.44 in 1Q 2024)

Pfizer Limited to Report Q1, 2025 Results on Jul 29, 2024

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024

Pfizer Limited to Report Q4, 2024 Results on May 17, 2024

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet

Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024

Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share Price

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors

Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)

Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023

Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead

Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023

New major risk - Revenue and earnings growth

Pfizer Limited Announces Change in Management, Effective September 1, 2023

Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023

Upcoming dividend of ₹40.00 per share at 0.9% yield

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited, Annual General Meeting, Aug 18, 2023

Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023

Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections

Price target decreased by 7.9% to ₹4,595

Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023

Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly

Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022)

Pfizer India Appoints Meenakshi Nevatia as CEO

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Upcoming dividend of ₹30.00 per share

Pfizer Limited Announces Interim (Special) Dividend for the Financial Year Ending March 31, 2023, Payable on or Before September 30, 2022

Pfizer Limited Approves Declaration of Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹35.00 per share

Pfizer Announces Resignation of S. Sridhar as Managing Director

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

Mylan Pharmaceuticals Private Limited completed the acquisition of off-patent branded and generic established medicines business from Pfizer Limited (BSE:500680).

Pfizer Limited to Report Q1, 2023 Results on Aug 05, 2022

A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)

Now 20% undervalued after recent price drop

Price target decreased to ₹5,201